Scholars Central

Review articlePublished 23 Jan 2019

Mesalazine-Induced Cardiotoxicity

Authors: Mohammad Inamul Haq, Shakeel Ahmed, Waseem Pasha, Syed Anwer Ali Zaidi

Journal of Rare Disorders: Diagnosis & Therapy

Volume 4 · Issue 6 · Pages 24

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Inflammatory bowel disease (IBD) which includes ulcerative colitis and Crohn’s disease can also affect other organs in the body including heart as extra-intestinal manifestation. Mesalazine is commonly used to treat this chronic inflammatory disorder and is usually well tolerated by most patients. However, there are certain situations where toxic effects of mesalazine involve heart, making it difficult to differentiate between extra-intestinal manifestation and a treatment related complication. Aims/Objective: Main objective of this review was to determine features that can help early recognition of mesalazine-induced cardiac involvement. Moreover, relationship between mesalazine dose and occurrence of cardiotoxicity was also observed. Finally, management of this condition including role of re-challenge in these patients was evaluated. Methods: A literature search for relevant studies of the MEDLINE database was conducted, including reported cases of mesalazine-induced cardiac involvement since 1989. Findings: Mesalazine-induced myopericarditis usually occurs within 2–4 weeks of initial drug exposure but may be delayed due to concomitant steroid use. There does not appear to be a dose-dependent relationship. A clear improvement following discontinuation of the drug helps to make the diagnosis. Mesalazine discontinuation and steroids are successfully used for treatment. Re-challenge usually results in recurrence of cardiac involvement. Cardiac dysfunction resolves completely with a return to previous baseline function. Thiopurines and anti-TNF therapies are used to manage inflammatory bowel disease. Conclusions: It is very important to evaluate any patient presenting with fever, shortness of breath or chest pain within 4 weeks of initiating mesalazine for possible drug-induced inflammation. Mesalazine should be stopped immediately and patient should be treated with steroids. Inflammatory bowel disease should be managed with second line drugs including thiopurines and anti-TNF therapies.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Rare Disorders: Diagnosis & Therapy.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Rare Disorders: Diagnosis & Therapy
  • SubjectCardiology
  • SubjectGastroenterology & Hepatology
  • BylineArticles whose byline prints “Mohammad Inamul Haq”
  • BylineArticles whose byline prints “Shakeel Ahmed”
  • BylineArticles whose byline prints “Waseem Pasha”
  • BylineArticles whose byline prints “Syed Anwer Ali Zaidi”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels